Kamada Overview
Kamada is a plasma-derived protein therapeutics company with a commercial product portfolio and a late-stage clinical pipeline. The company uses its proprietary platform technology and expertise for the extraction and purification of proteins from human plasma. The company has two FDA-approved products: GLASSIA, intravenous plasma-derived Alpha-1 Antitrypsin (AAT) for the treatment of AAT deficiency, marketed in the United States through a strategic partnership with Shire Plc; and KEDRAB, a rabies immune globulin (human) product distributed in the United States by Kedrion. Kamada also sells an additional four plasma-derived pharmaceutical products in approximately 20 markets. Kamada has products in late-stage clinical development, including an inhaled formulation of AAT and intravenous AAT for the treatment of type 1 diabetes and GvHD and the prevention of lung transplant rejection.
Cumulative Funding Raised Over Time ($)
$25.0MJan 2020
$45.0MJun 2009
$105.0MMay 2023
$135.0MNov 2019
Latest News
KMDA vs. NVZMY: Which Stock Is the Better Value Option?
growth-positive
Wall Street Analysts Believe Kamada (KMDA) Could Rally 113.15%: Here's is How to Trade
Kamadas stock (KMDA) has seen a 1.2% increase over the past four weeks, closing at $6.92. Analysts have set a mean price target of $14.75, suggesting a potential upside of 113.2%. The price targets range from $11.00 to $20.00, with a standard deviation of $3.86, indicating a high degree of agreement among analysts. Despite skepticism about the reliability of price targets, the consensus suggests potential growth, supported by expected better-than-estimated earnings. Analysts optimism may be influenced by business incentives, but the tight clustering of targets could guide further research into the stocks potential.
growth-positive
Kamada to Present at the Stifel 2025 Healthcare Conference
Kamada Ltd., a global biopharmaceutical company, announced its participation in the Stifel 2025 Healthcare Conference, where CEO Amir London will present and hold investor meetings. The company focuses on specialty plasma-derived therapies and has a portfolio of FDA-approved products. Kamada is pursuing growth through commercial activities, business development, and expanding plasma collection operations. The company is advancing its lead product candidate, Inhaled AAT, in a Phase 3 clinical trial. FIMI Opportunity Funds is the controlling shareholder, owning 38% of the shares.
Product StageInvestmentPartners
growth-positive
High Growth Tech Stocks Including LINK Mobility Group Holding And 2 More
LINK Mobility Group Holding ASA, a company offering mobile and communication-platform-as-a-service solutions, has recently experienced a notable stake acquisition by an undisclosed buyer for approximately NOK 520 million. Despite a challenging quarter with a drop in sales and a swing to a net loss, LINKs strategic acquisitions, such as SMSPortal, are expected to bolster future growth. The company is actively pursuing value creation through both organic growth and strategic mergers and acquisitions, with annual earnings projected to surge by 61%, significantly outpacing the Norwegian markets growth rate. LINK Mobilitys operations span Central, Western, and Northern Europe, as well as Global Messaging.
Acquisition
growth-positive
3 Reasons Why Growth Investors Shouldn't Overlook Kamada (KMDA)
The article discusses Kamada, a biopharmaceutical company, highlighting its potential as a growth stock. Kamada is recommended by the Zacks Growth Style Score system due to its favorable growth score and top Zacks Rank. The companys projected EPS growth of 57.3% this year significantly surpasses the industry average of 19.3%. Additionally, Kamadas asset utilization ratio of 0.46 indicates efficient asset use compared to the industry average of 0.31. The companys sales are also expected to grow by 12.4% this year, further emphasizing its growth potential. Overall, Kamada is portrayed as a strong growth investment opportunity.
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $150M |
| Last funding | $60M |
| Stage | Public |
| Rounds | 7 |
| Investors | 2 |
Team Members
4
Employees: 201-500
Web & Social Links
| Website | www.kamada.com |
| Careers | Careers page |
Locations
Beit Kama, Israel
Haim Holtsman St 2, Rehovot, Israel
Photos & Videos
3 item(s)
Kamada Business
Business models
B2B
Product stage
Released
Employees
201-500
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentBiomaterials & Tissue EngineeringTarget Customer
Healthcare & Life SciencesHealthcareProvidersLife SciencesPharmaceuticalsCore Technology
BiologicalsTags (14)
therapeuticsinhalationpulmonarybiopharmaceuticaldiabetescritical-carerespiratorypharmaceuticalsanti-inflammatorydoctorshospitalsproteinsorphan-drughealthcare-providersGeographic Markets
GlobalKamada Financials
$150M
Total funding
Undisclosed
Capital raised
$60M
Last funding
Public
Funding stage
7
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$25.0MJan 2020
$45.0MJun 2009
$105.0MMay 2023
$135.0MNov 2019
Private Equity Funding
PIPE
May 2023
$60M
FIMI Opportunity Funds (Lead)
PIPE
Jan 2020
$25M
FIMI Opportunity Funds
PIPE
Nov 2019
$30M
FIMI Opportunity Funds
PIPE
Jun 2009
$20M
Hercules Capital, Inc.
Public Offering / Exit
POEvent
Jul 2017
Undisclosed
POEvent
Jun 2008
Undisclosed
POEvent
Sep 2005
Undisclosed
Mergers & Acquisitions
MNAEvent
Feb 2021
$1.63M
Kamada Lifecycle
Cumulative Funding Raised Over Time
$25.0MJan 2020
$45.0MJun 2009
$105.0MMay 2023
$135.0MNov 2019
All Events
PIPE
May 2023
$60M
FIMI Opportunity Funds (Lead)
PIPE
Jan 2020
$25M
FIMI Opportunity Funds
PIPE
Nov 2019
$30M
FIMI Opportunity Funds
PIPE
Jun 2009
$20M
Hercules Capital, Inc.
POEvent
Jul 2017
Undisclosed
POEvent
Jun 2008
Undisclosed
POEvent
Sep 2005
Undisclosed
MNAEvent
Feb 2021
$1.63M
Kamada News
158 articlesKMDA vs. NVZMY: Which Stock Is the Better Value Option?
growth-positive
Wall Street Analysts Believe Kamada (KMDA) Could Rally 113.15%: Here's is How to Trade
Kamadas stock (KMDA) has seen a 1.2% increase over the past four weeks, closing at $6.92. Analysts have set a mean price target of $14.75, suggesting a potential upside of 113.2%. The price targets range from $11.00 to $20.00, with a standard deviation of $3.86, indicating a high degree of agreement among analysts. Despite skepticism about the reliability of price targets, the consensus suggests potential growth, supported by expected better-than-estimated earnings. Analysts optimism may be influenced by business incentives, but the tight clustering of targets could guide further research into the stocks potential.
growth-positive
Kamada to Present at the Stifel 2025 Healthcare Conference
Kamada Ltd., a global biopharmaceutical company, announced its participation in the Stifel 2025 Healthcare Conference, where CEO Amir London will present and hold investor meetings. The company focuses on specialty plasma-derived therapies and has a portfolio of FDA-approved products. Kamada is pursuing growth through commercial activities, business development, and expanding plasma collection operations. The company is advancing its lead product candidate, Inhaled AAT, in a Phase 3 clinical trial. FIMI Opportunity Funds is the controlling shareholder, owning 38% of the shares.
Product StageInvestmentPartners
growth-positive
High Growth Tech Stocks Including LINK Mobility Group Holding And 2 More
LINK Mobility Group Holding ASA, a company offering mobile and communication-platform-as-a-service solutions, has recently experienced a notable stake acquisition by an undisclosed buyer for approximately NOK 520 million. Despite a challenging quarter with a drop in sales and a swing to a net loss, LINKs strategic acquisitions, such as SMSPortal, are expected to bolster future growth. The company is actively pursuing value creation through both organic growth and strategic mergers and acquisitions, with annual earnings projected to surge by 61%, significantly outpacing the Norwegian markets growth rate. LINK Mobilitys operations span Central, Western, and Northern Europe, as well as Global Messaging.
Acquisition
growth-positive
3 Reasons Why Growth Investors Shouldn't Overlook Kamada (KMDA)
The article discusses Kamada, a biopharmaceutical company, highlighting its potential as a growth stock. Kamada is recommended by the Zacks Growth Style Score system due to its favorable growth score and top Zacks Rank. The companys projected EPS growth of 57.3% this year significantly surpasses the industry average of 19.3%. Additionally, Kamadas asset utilization ratio of 0.46 indicates efficient asset use compared to the industry average of 0.31. The companys sales are also expected to grow by 12.4% this year, further emphasizing its growth potential. Overall, Kamada is portrayed as a strong growth investment opportunity.
growth-positive
Are Investors Undervaluing Kamada (KMDA) Right Now?
The article discusses Kamada Ltd. (KMDA), highlighting its strong position as a value stock according to the Zacks Rank system. Kamada is currently rated as a Buy with an A grade for Value, showcasing favorable valuation metrics such as a Forward P/E ratio of 16.85, a P/B ratio of 1.53, and a P/S ratio of 2.29, all of which are lower than industry averages. These metrics suggest that Kamada is undervalued, making it an attractive option for value investors. The article emphasizes the companys solid earnings outlook, reinforcing its potential as a strong investment choice.
growth-positive
KMDA or ILMN: Which Is the Better Value Stock Right Now?
The article compares Kamada (KMDA) and Illumina (ILMN) in terms of their attractiveness to value investors. Kamada is highlighted as a better value investment due to its stronger Zacks Rank of #2 (Buy) compared to Illuminas #3 (Hold). Kamadas valuation metrics, such as a forward P/E ratio of 17.34 and a PEG ratio of 0.69, are more favorable than Illuminas. The article suggests that Kamadas solid earnings outlook and valuation figures make it a superior value option. The analysis is based on traditional valuation metrics used by value investors.
growth-positive
Does Kamada (KMDA) Have the Potential to Rally 114.39% as Wall Street Analysts Expect?
Kamada (KMDA) has seen a 0.7% increase in its stock price over the past four weeks, closing at $6.88. Analysts have set a mean price target of $14.75, suggesting a potential upside of 114.4%. The estimates vary, with the lowest at $11.00 and the highest at $20.00, indicating a potential increase of 59.9% to 190.7%. Despite the variability in estimates, analysts agree that Kamada will report better-than-expected earnings, which could drive the stock price higher. However, the reliability of price targets is debated, as they may be influenced by business incentives. A low standard deviation in price targets suggests analyst agreement, which could be a basis for further research into the stocks potential.
growth-positive
Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes"
The article highlights Kamada (KMDA) as a promising growth stock, recommended by the Zacks Growth Style Score system. Kamada, a biopharmaceutical company, is noted for its strong growth prospects, with a projected EPS growth of 57.3% this year, significantly outperforming the industry average of 18.3%. The company also demonstrates efficient asset utilization with a sales-to-total-assets ratio of 0.46, compared to the industry average of 0.31. Additionally, Kamadas sales are expected to grow by 12.4% this year, further emphasizing its potential as a growth stock. The article suggests that Kamadas combination of high growth scores and strong Zacks Rank makes it an attractive option for growth investors.
growth-positive
Should Value Investors Buy Kamada (KMDA) Stock?
The article discusses Kamada (KMDA), highlighting its strong position as a value stock according to Zacks Investment Research. Kamada is currently rated as a Zacks Rank #2 (Buy) and has a Value grade of A. The companys P/E, P/B, and P/S ratios are favorable compared to industry averages, suggesting that Kamada is undervalued. The article emphasizes the importance of these valuation metrics for value investors and suggests that Kamadas earnings outlook makes it one of the markets strongest value stocks.
growth-positive
KMDA vs. ILMN: Which Stock Is the Better Value Option?
The article compares Kamada (KMDA) and Illumina (ILMN) in terms of their value for investors, focusing on their Zacks Rank and various valuation metrics. Kamada has a Zacks Rank of #2 (Buy) and is highlighted as a better value option compared to Illumina, which has a Zacks Rank of #3 (Hold). Kamadas valuation metrics, such as a lower forward P/E ratio and PEG ratio, contribute to its higher Value grade of A compared to Illuminas C. The article suggests that Kamadas solid earnings outlook and valuation figures make it a superior investment choice at present.
growth-positive
High Growth Tech Stocks with Promising Global Potential
Stemmer Imaging AG, a company specializing in machine vision technology, is poised for significant growth despite recent leadership changes. With a market capitalization of €377 million, the company is transitioning from a distribution model to a systems house, which has broadened its market reach globally. This strategic shift is expected to drive an annual revenue increase of 11.6% and a 41% surge in earnings. The leadership transition involves Paul Scholten stepping in as interim CEO following Arne Dehns departure. Stemmer Imagings evolution in the tech sector is set to enhance its influence and financial performance, capitalizing on the growing demand for machine vision solutions.
Management Changes
growth-positive
Are Investors Undervaluing Kamada (KMDA) Right Now?
The article discusses Kamada Ltd. (KMDA), highlighting its strong value proposition as a stock. Kamada is currently rated as a Zacks Rank #2 (Buy) and has an A grade for Value, indicating it is undervalued compared to its industry peers. The company has a Forward P/E ratio of 16.67, which is lower than the industry average of 35.81, and a P/B ratio of 1.51, also below the industry average of 3.13. These metrics suggest that Kamada is a strong value stock with a promising earnings outlook. The article emphasizes the importance of value investing and suggests that Kamada is a great stock to consider for value investors.
growth-positive
Wall Street Analysts See an 110.11% Upside in Kamada (KMDA): Can the Stock Really Move This High?
Kamada (KMDA) recently closed at $7.02, marking a 2.5% gain over the past four weeks. Analysts have set a mean price target of $14.75, suggesting a potential upside of 110.1%. The price targets range from $11.00 to $20.00, with a standard deviation of $3.86, indicating a strong consensus among analysts. Despite skepticism about the reliability of price targets, the consensus and positive earnings estimate revisions suggest potential growth for Kamada. Analysts price targets often reflect business incentives, but a low standard deviation indicates agreement on the stocks potential direction. This could serve as a basis for further research into Kamadas fundamental drivers.
growth-positive
Kamada (KMDA) is an Incredible Growth Stock: 3 Reasons Why
The article highlights Kamada, a biopharmaceutical company, as a promising growth stock according to the Zacks Growth Style Score. Kamada is noted for its strong growth prospects, with an expected EPS growth of 50.7% this year, significantly outperforming the industry average of 18.4%. The companys asset utilization ratio of 0.46 indicates efficient use of assets to generate sales, compared to the industry average of 0.31. Kamadas sales are also projected to grow by 12.4% this year, further emphasizing its potential as a growth stock. The article suggests that Kamadas combination of a favorable Growth Score and top Zacks Rank makes it an attractive option for growth investors.
growth-positive
Halozyme Therapeutics, Inc. (HALO) Hit a 52 Week High, Can the Run Continue?
Halozyme Therapeutics has seen a significant increase in its stock price, rising 20.6% over the past month and reaching a new 52-week high. The company has consistently outperformed earnings expectations, with a notable EPS of $1.54 against an estimated $1.23 in its last report. For the current fiscal year, earnings are projected to grow by 46.1% with a 29.58% increase in revenues. The companys stock is currently trading at 11.9 times its fiscal year EPS estimates, which is below the industry average. Halozyme has a Zacks Rank of #1 (Strong Buy) due to favorable earnings estimate revisions.
growth-positive
Kamada to Participate in Upcoming September Investor Conferences
Kamada Ltd., a global biopharmaceutical company, announced its participation in the 2025 Wells Fargo Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference. CEO Amir London will present at both events and engage in one-on-one investor meetings. Kamada focuses on growth through commercial activities, business development, and expanding plasma collection operations. The company has a portfolio of FDA-approved products and is advancing its lead product candidate, Inhaled AAT, in a Phase 3 clinical trial. FIMI Opportunity Funds is the controlling shareholder, owning 38% of Kamadas shares.
Product StageInvestment
growth-positive
Should Value Investors Buy Kamada (KMDA) Stock?
The article discusses Kamada Ltd. (KMDA), highlighting its potential as a value stock. Kamada is currently rated as a Zacks Rank #2 (Buy) with an A grade for Value. The companys P/E ratio of 17.23 is significantly lower than the industry average of 36.32, suggesting it may be undervalued. Similarly, its P/B ratio of 1.55 and P/S ratio of 2.35 are also favorable compared to industry averages. These metrics, along with a strong earnings outlook, indicate that Kamada is a promising investment opportunity for value investors.
growth-positive
KMDA or ARGX: Which Is the Better Value Stock Right Now?
The article compares two companies, Kamada (KMDA) and argenex SE (ARGX), in the Medical - Biomedical and Genetics sector, focusing on their valuation metrics and Zacks Rank. Kamada is highlighted as the better option for value investors due to its stronger earnings estimate revisions and more attractive valuation metrics, such as a lower forward P/E ratio and PEG ratio compared to argenex SE. Kamada has a Zacks Rank of #2 (Buy), indicating a positive earnings outlook, while argenex SE has a Zacks Rank of #3 (Hold). The article suggests that Kamada is currently undervalued and a superior choice for investors seeking value stocks.
growth-positive
3 Reasons Growth Investors Will Love Kamada (KMDA)
The article highlights Kamada, a biopharmaceutical company, as a promising growth stock according to the Zacks Growth Style Score. Kamada is recommended due to its favorable Growth Score and top Zacks Rank. The companys projected EPS growth of 50.7% this year significantly surpasses the industry average of 18.4%. Additionally, Kamada exhibits strong asset utilization with a sales-to-total-assets ratio of 0.46, compared to the industry average of 0.31. The companys sales are expected to grow by 12.4% this year, indicating strong growth prospects. Overall, Kamada is positioned as an efficient and promising growth stock.
growth-positive
What Makes Kamada (KMDA) a New Buy Stock
Kamada (KMDA) has been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook on its earnings estimates. This upgrade is based on an upward trend in earnings estimates, which is a significant factor influencing stock prices. The Zacks rating system, which tracks EPS estimates, is a valuable tool for investors as it reflects changes in a companys earnings potential. The upgrade suggests an improvement in Kamadas underlying business, which could lead to a higher stock price as investors recognize this trend. The Zacks Rank system has a strong track record, with top-ranked stocks historically generating substantial returns.
growth-positive
Kamada Ltd (KMDA) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Increased ...
Kamada Ltd reported strong financial results for the first half of 2025, with total revenues of $88.8 million, an 11% increase year-over-year. The companys adjusted EBITDA rose by 35%, indicating improved profitability. Kamada is advancing its pivotal phase 3 inhaled clinical program and successfully launched its first biosimilar product in Israel, with plans to launch two more later this year. These developments are expected to contribute to future revenue growth. Despite a decrease in gross profit margins due to changes in product and territory sales mix, the company remains confident in its growth prospects. However, the competitive landscape for its inhaled AAT program is evolving, and its cash position has declined, potentially limiting future business development activities.
Product StageCustomers
growth-positive
KMDA vs. ILMN: Which Stock Is the Better Value Option?
The article compares Kamada (KMDA) and Illumina (ILMN) in terms of their value for investors, focusing on their Zacks Rank and valuation metrics. Kamada is highlighted as a better value investment due to its superior earnings outlook and valuation metrics, such as a lower P/E and PEG ratio compared to Illumina. Kamada has a forward P/E ratio of 21.09 and a PEG ratio of 0.84, indicating better expected earnings growth. The article suggests that Kamada is a superior value option for investors seeking undervalued stocks. No specific investment or partnership events are mentioned.
growth-positive
Unearthing Middle East's Hidden Stock Gems In August 2025
Atreyu Capital Markets Ltd, a financial services company based in Israel, has demonstrated impressive growth in the Middle East market. The company, which operates in the investment management sector, reported a significant increase in earnings, up 29.3% over the past year, outperforming its industry peers. With a market capitalization of ₪1.22 billion, Atreyu Capital Markets has shown robust financial performance, with revenue climbing to ILS 27.56 million from ILS 22.23 million year-on-year. The company is debt-free and has a price-to-earnings ratio of 12.4x, which is below the IL market average, indicating a strong value proposition. This performance could attract investors looking for opportunities in emerging markets.
growth-positive
Are Investors Undervaluing Kamada (KMDA) Right Now?
The article discusses Kamada (KMDA), highlighting its strong position as a value stock according to Zacks Investment Research. Kamada is currently rated as a Zacks Rank #2 (Buy) and has an A grade for Value. The companys P/E, P/B, and P/S ratios are all favorable compared to industry averages, suggesting that the stock is undervalued. This makes Kamada an attractive option for value investors. The article emphasizes the importance of these metrics in identifying strong stocks and suggests that Kamadas earnings outlook further supports its status as a strong value stock.
growth-positive
High Growth Tech Stocks to Watch in August 2025
Skyworth Digital Co., Ltd. is a global manufacturer of home video entertainment and intelligent connectivity solutions, with a market cap of CN¥13.44 billion. The company is navigating a challenging tech landscape with a robust future potential, expecting an annual earnings growth of 43.6%, which is significantly higher than the Chinese market average. Despite a slower revenue growth rate of 13.3%, Skyworth maintains its competitive edge through strategic investments in innovation and technology development. The companys commitment to expanding its technological capabilities is expected to reshape its market standing and fuel long-term growth, even as profit margins currently linger at 1.8%.
growth-positive
Kamada: Q2 Earnings Snapshot
Kamada Ltd., a biopharmaceutical company based in Rehovot, Israel, reported second-quarter earnings of $7.4 million, or 13 cents per share, surpassing Wall Street expectations of 9 cents per share. However, the companys revenue for the period was $44.8 million, slightly below the forecasted $45.1 million by analysts surveyed by Zacks Investment Research. Despite the revenue miss, the earnings report is considered growth-positive due to the higher-than-expected net income. The article was generated using data from Zacks Investment Research.
growth-negative
Kamada (KMDA) Reports Q2 Earnings: What Key Metrics Have to Say
Kamada reported its financial results for the quarter ended June 2025, with revenue of $44.75 million, marking a 5.4% increase from the previous year. However, this was slightly below the Zacks Consensus Estimate of $45.06 million, resulting in a revenue surprise of -0.67%. The companys EPS was $0.13, exceeding the consensus estimate of $0.09 by 44.44%. Despite the positive EPS surprise, Kamadas stock has underperformed, with a -1.1% return over the past month compared to the S&P 500s +3.1%. The company holds a Zacks Rank #3 (Hold), suggesting it may perform in line with the market.
growth-positive
Kamada Reports Strong Second Quarter and First Half 2025 Financial Results with 11% Year-Over-Year 6-Month Top Line Growth and a 35% Increase in Profitability; Raises Full-Year Profitability Guidance
Kamada Ltd., a biopharmaceutical company, reported strong financial results for the first half of 2025, with total revenues of $88.8 million, an 11% increase year-over-year. The company also announced FDA approval for its plasma collection center in Houston, Texas, which is now cleared for commercial sales. Kamada is focusing on securing commercial-stage business development opportunities and expanding its portfolio of marketed products. The company is advancing its Phase 3 InnovAATe clinical trial for inhaled Alpha-1 Antitrypsin therapy and expects to conduct an interim futility analysis by the end of the year. The positive financial outlook supports increased adjusted EBITDA guidance for 2025.
FDA approvedProduct StageInvestment
growth-positive
Kamada (KMDA) Q2 Earnings Top Estimates
Kamada reported quarterly earnings of $0.13 per share, surpassing the Zacks Consensus Estimate of $0.09 per share, marking an earnings surprise of +44.44%. The companys revenues for the quarter were $44.75 million, slightly below the consensus estimate by 0.67%. Despite missing revenue expectations, Kamadas stock has risen by about 22.8% since the beginning of the year, outperforming the S&P 500s gain of 9.6%. The companys earnings outlook and estimate revisions will be crucial for its future stock performance. Currently, Kamada holds a Zacks Rank #3 (Hold), indicating expected market-aligned performance.
growth-negative
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Beats Revenue Estimates
Liquidia Technologies, Inc. reported a quarterly loss of $0.49 per share, missing the Zacks Consensus Estimate of a $0.43 loss. This represents a negative earnings surprise of 13.95%. Despite the earnings miss, the company posted revenues of $8.84 million, surpassing estimates by 124.46%. Over the last four quarters, Liquidia has not exceeded consensus EPS estimates but has outperformed revenue expectations twice. The companys stock has risen by 80.3% since the start of the year, outperforming the S&P 500s 8.4% gain. The future stock performance will depend on managements commentary and earnings outlook. The current Zacks Rank for Liquidia is #3 (Hold), indicating expected market performance in the near term.
growth-positive
Kamada Announces FDA Approval of its Plasma Collection Center in Houston, Texas
Kamada Ltd., a global biopharmaceutical company, has received FDA approval for its plasma collection center in Houston, Texas. This state-of-the-art facility, with a capacity of 50,000 liters annually, is expected to contribute $8 million to $10 million in revenue at full capacity. The approval follows an FDA inspection and allows Kamada to commence commercial sales of normal source plasma. Kamada plans to seek further approval from the European Medicines Agency. The company operates three plasma collection centers in Texas and aims to expand its operations to support revenue growth. FIMI Opportunity Funds is the controlling shareholder, owning 38% of Kamadas shares.
Product StageFDA approved/pending approval
growth-positive
Exploring Analyst Estimates for Kamada (KMDA) Q2 Earnings, Beyond Revenue and EPS
The article discusses Kamadas upcoming earnings report, with Wall Street analysts projecting quarterly earnings of $0.09 per share, a 12.5% increase year-over-year. Revenues are expected to reach $45.06 million, a 6.1% increase from the previous year. Despite a recent 12.1% decline in Kamadas share price, the companys Zacks Rank #3 (Hold) suggests its performance will align with the overall market. Analysts have also provided estimates for Kamadas key metrics, including Revenues- Distribution and Revenues- Proprietary products, both showing positive year-over-year changes. The article emphasizes the importance of earnings estimate revisions as indicators of potential stock price movements.
growth-negative
Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates
Verastem reported a quarterly loss of $0.39 per share, which was better than the Zacks Consensus Estimate of a loss of $0.85, marking an earnings surprise of +54.12%. However, the companys revenue for the quarter was $2.14 million, significantly missing the consensus estimate by 86.36%. Despite outperforming the market with a 10.6% share price increase since the beginning of the year, Verastems earnings outlook remains uncertain. The company has not been able to beat consensus revenue estimates over the last four quarters, and its Zacks Rank #4 (Sell) suggests it may underperform in the near future.
growth-positive
Kamada to Announce Second Quarter and First Half Ended June 30, 2025 Financial Results on August 13, 2025
Kamada Ltd., a global biopharmaceutical company, is set to release its financial results for the second quarter and first half of 2025 on August 13, 2025. The company, which specializes in plasma-derived therapies for rare and serious conditions, will host a conference call to discuss these results. Kamadas strategy focuses on organic growth, business development, and expanding plasma collection operations. The company is advancing its lead product candidate, Inhaled AAT, through a Phase 3 clinical trial. FIMI Opportunity Funds, a leading private equity firm in Israel, is the controlling shareholder, owning 38% of Kamadas shares.
Product StageInvestmentFDA approved/pending approval
growth-positive
KMDA or ACAD: Which Is the Better Value Stock Right Now?
The article compares Kamada (KMDA) and Acadia Pharmaceuticals (ACAD) in terms of value investing, highlighting Kamada as the superior option. Kamada holds a Zacks Rank of #2 (Buy) and has a strong earnings outlook, with favorable valuation metrics such as a forward P/E ratio of 23.88 and a PEG ratio of 0.96. In contrast, Acadia has a higher forward P/E ratio of 42.40 and a PEG ratio of 4.51. Kamadas Value grade is A, indicating it is undervalued compared to Acadia, which has a Value grade of C. The article suggests Kamada is a better choice for value investors.
growth-positive
Is Kamada (KMDA) Stock Undervalued Right Now?
The article discusses Kamada Ltd. (KMDA), highlighting its strong position as a value stock. Kamada is currently rated as a Buy with a Zacks Rank #2 and a Value grade of A. The companys stock is trading with a P/E ratio of 21.4, which is lower than the industry average of 37.33, indicating it may be undervalued. Additionally, Kamadas P/B ratio of 1.77 and P/S ratio of 2.71 are also favorable compared to industry averages. These metrics suggest that Kamada is an attractive option for value investors, supported by a strong earnings outlook.
growth-positive
Strength Seen in Kamada (KMDA): Can Its 9.5% Jump Turn into More Strength?
Kamada (KMDA) shares surged by 9.5% in the last trading session, closing at $7.95, driven by increased trading volume and investor optimism. The company, known for its specialty plasma-derived therapies, recently reported strong financial results for Q1 2025. Kamada is expected to post quarterly earnings of $0.09 per share, a 12.5% increase year-over-year, with revenues projected at $45.06 million, up 6.1% from the previous year. The stock holds a Zacks Rank #2 (Buy), indicating positive sentiment. Investors are advised to monitor KMDA for potential continued strength.
growth-positive
Should Value Investors Buy Kamada (KMDA) Stock?
The article discusses Kamada Ltd. (KMDA), highlighting its current status as a value stock with a Zacks Rank of #2 (Buy) and a Value grade of A. The companys Forward P/E ratio is 21.37, which is favorable compared to the industry average of 37.93. Additionally, Kamadas P/B ratio is 1.63, lower than the industry average of 3.16, indicating that the stock may be undervalued. The article suggests that Kamadas strong earnings outlook and valuation metrics make it an attractive option for value investors. The article is published by Zacks Investment Research.
growth-positive
KMDA vs. ACAD: Which Stock Is the Better Value Option?
The article compares Kamada (KMDA) and Acadia Pharmaceuticals (ACAD) as potential value stocks in the Medical - Biomedical and Genetics sector. Kamada is highlighted as a more attractive option for value investors due to its strong Zacks Rank of #2 (Buy) and superior valuation metrics, including a lower forward P/E ratio and PEG ratio compared to Acadia. Kamada also boasts a better earnings outlook, earning it a Value grade of A, while Acadia receives a C. The article emphasizes the importance of various valuation metrics in assessing the potential of these stocks.
growth-positive
Kamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle East
Kamada Ltd., a global biopharmaceutical company, announced that despite evolving circumstances in the Middle East, its operations and manufacturing in Israel continue without interruption. The company has sufficient product availability in its distribution centers and with partners worldwide to meet client demands. Kamada focuses on business continuity and employee well-being while monitoring the situation closely. The company is advancing its growth strategy through organic growth, business development, and expanding plasma collection operations. Kamadas lead product candidate, Inhaled AAT, is progressing in a Phase 3 clinical trial. FIMI Opportunity Funds is the controlling shareholder, owning 38% of the companys shares.
Product StageCustomersPartnersFDA approved/pending approval
growth-positive
Implied Volatility Surging for Kamada Stock Options
The article discusses the recent high implied volatility in the options market for Kamada Ltd., indicating potential significant movement in the companys stock. Kamada is currently rated as a Zacks Rank #2 (Buy) in the Medical - Biomedical and Genetics Industry. Analysts have increased their earnings estimates for the current quarter, suggesting a positive outlook. The high implied volatility may present trading opportunities for options traders, particularly those looking to sell premium. The article highlights the potential for profit while managing risk through strategic options trading.
growth-positive
Are Investors Undervaluing Kamada (KMDA) Right Now?
The article discusses Kamada Ltd. (KMDA), highlighting its strong value proposition for investors. With a Zacks Rank of #2 (Buy) and a Value grade of A, Kamada is considered an attractive stock due to its favorable valuation metrics, including a P/E ratio of 20.75 and a P/B ratio of 1.57, both of which are lower than the industry averages. The article emphasizes the potential for growth and profitability, making Kamada a compelling choice for value investors. The focus is on traditional valuation metrics that suggest the stock is undervalued, offering room for profits.
growth-positive
Wall Street Analysts Think Kamada (KMDA) Could Surge 106.86%: Read This Before Placing a Bet
Kamada (KMDA) has seen a 2.9% increase in its stock price over the past four weeks, closing at $6.85. Analysts have set a mean price target of $14.17, indicating a potential upside of 106.9%. The price targets range from $11 to $20, with a standard deviation of $3.13, suggesting a high degree of agreement among analysts. Despite skepticism about the reliability of price targets, the consensus suggests potential growth for Kamada. Analysts also anticipate better-than-expected earnings for the company, further supporting the positive outlook. However, its noted that analysts price targets can be influenced by business incentives, leading to overly optimistic projections.
growth-positive
KMDA vs. CSLLY: Which Stock Should Value Investors Buy Now?
The article compares two companies, Kamada (KMDA) and CSL Limited Sponsored ADR (CSLLY), in the Medical - Biomedical and Genetics sector, focusing on their value as investment opportunities. Kamada is highlighted as the better value option due to its stronger earnings outlook and favorable valuation metrics, such as a lower forward P/E ratio and PEG ratio compared to CSL Limited. Kamada holds a Zacks Rank of #2 (Buy) and a Value grade of A, indicating a solid investment opportunity. The article emphasizes the importance of valuation metrics like P/E, PEG, and P/B ratios in assessing a companys value.
growth-positive
Is Kamada (KMDA) Stock Undervalued Right Now?
The article discusses Kamada (KMDA), highlighting its strong position as a value stock according to the Zacks Rank system. Kamada is currently rated as a #2 (Buy) with an A grade for Value. The company has a favorable Forward P/E ratio of 23.14 compared to the industry average of 36.13, and a PEG ratio of 0.93, indicating potential undervaluation. Other valuation metrics such as P/B and P/S ratios also suggest that Kamada is undervalued relative to its industry peers. The article emphasizes Kamadas strong earnings outlook and its potential as an impressive value stock.
growth-positive
Wall Street Analysts Believe Kamada (KMDA) Could Rally 106.56%: Here's is How to Trade
Kamada (KMDA) has seen a 5.5% increase in its stock price over the past four weeks, closing at $6.86. Analysts have set a mean price target of $14.17, indicating a potential upside of 106.6%. The price targets range from $11 to $20, with a standard deviation of $3.13, suggesting strong agreement among analysts. While price targets are often criticized for being overly optimistic, the consensus among analysts and positive earnings estimate revisions suggest potential growth for Kamada. However, investors are cautioned against relying solely on price targets for investment decisions, as they can be misleading.
growth-positive
Kamada Ltd (KMDA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion
Kamada Ltd reported a strong first quarter with a 17% increase in total revenues, reaching $44 million, and a 54% increase in adjusted EBITDA. The company reiterated its annual guidance for 2025 and is advancing its growth strategy, which includes organic growth, business development, M&A, and plasma collection operations. A new plasma collection center in San Antonio is expected to significantly contribute to revenues. Cytogam did not contribute significantly to growth this quarter, and enrollment for the phase 3 inhaled Alpha 1 program is at 55%, indicating potential delays. The company faces uncertainties related to global trade tariffs but does not anticipate a direct impact.
Product StageExpand
growth-positive
Kamada (KMDA) Q1 Earnings Match Estimates
Kamada reported quarterly earnings of $0.07 per share, aligning with the Zacks Consensus Estimate and improving from $0.04 per share a year ago. The company, part of the Zacks Medical - Biomedical and Genetics industry, achieved revenues of $44.02 million, exceeding the consensus estimate by 5.28% and surpassing year-ago revenues of $37.74 million. Kamada has consistently outperformed revenue estimates in three of the last four quarters. The stock has risen by 13.1% since the beginning of the year, outperforming the S&P 500s 0.1% gain. The companys earnings outlook remains crucial for future stock movements, with a current Zacks Rank of #3 (Hold). The consensus EPS estimate for the upcoming quarter is $0.07 on $44.55 million in revenues.
growth-positive
Compared to Estimates, Kamada (KMDA) Q1 Earnings: A Look at Key Metrics
Kamada (KMDA) reported a revenue of $44.02 million for the quarter ended March 2025, marking a 16.6% increase compared to the same period last year. The earnings per share (EPS) was $0.07, consistent with the consensus estimate. The revenue exceeded the Zacks Consensus Estimate by 5.28%, driven by strong performance in proprietary products, which saw an 18.5% year-over-year increase. Despite a slight underperformance in distribution revenue, the companys overall financial performance was positive. Kamadas stock has returned 9.5% over the past month, aligning closely with the broader market. The company holds a Zacks Rank #3 (Hold), suggesting it may perform in line with the market in the near term.
growth-positive
Kamada: Q1 Earnings Snapshot
Kamada Ltd., a biopharmaceutical company based in Rehovot, Israel, reported a first-quarter net income of $4 million, translating to a profit of 7 cents per share. This result met Wall Street expectations, as well as the average estimate of three analysts surveyed by Zacks Investment Research. The companys revenue for the period was $44 million, exceeding the forecasted $41.8 million. Kamada anticipates full-year revenue to be between $178 million and $182 million. The article highlights the companys strong financial performance and positive outlook.
growth-positive
Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability
Kamada Ltd., a global biopharmaceutical company, reported strong financial results for Q1 2025, with revenues of $44 million, a 17% increase year-over-year, and an adjusted EBITDA of $11.6 million, up 54%. The company is focusing on organic growth, M&A, and expanding its plasma collection operations, including a new site in San Antonio, Texas. Kamada is also advancing its Phase 3 Inhaled AAT program and has launched a post-marketing research program for CYTOGAM® to enhance its use in preventing CMV disease in organ transplants. The company reiterates its 2025 revenue guidance of $178-$182 million.
Product StageExpand
growth-positive
Kamada (KMDA) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
The article discusses the projected quarterly earnings and revenue for Kamada (KMDA), with analysts expecting earnings of $0.07 per share, a 75% increase year over year, and revenues of $41.81 million, a 10.8% increase from the same quarter last year. The article highlights the importance of earnings estimate revisions as indicators of potential investor actions. Analysts predict Revenues from distribution to reach $5.72 million, a 43.8% increase, and Revenues from proprietary products to be $36.09 million, a 6.9% increase. Kamadas shares have increased by 18.3% in the past month, outperforming the Zacks S&P 500 composites 13.7% move. The company holds a Zacks Rank #3 (Hold), indicating it is expected to follow the overall market performance.
growth-positive
Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates
Puma Biotech reported quarterly earnings of $0.10 per share, surpassing the Zacks Consensus Estimate of $0.02 per share, marking a 400% earnings surprise. The company also reported revenues of $46 million, exceeding the consensus estimate by 4.65%. Over the last four quarters, Puma Biotech has consistently outperformed consensus EPS and revenue estimates. Despite a 2% decline in share price since the beginning of the year, the company has outperformed the S&P 500, which declined by 4.3%. The stocks future performance will depend on managements commentary and earnings outlook. Currently, Puma Biotech holds a Zacks Rank #1 (Strong Buy), indicating expected market outperformance.
growth-negative
Nuvation Bio Inc. (NUVB) Reports Q1 Loss, Tops Revenue Estimates
Nuvation Bio Inc. reported a quarterly loss of $0.16 per share, aligning with the Zacks Consensus Estimate, but worse than the $0.07 loss per share from a year ago. Despite surpassing revenue expectations with $3.08 million, the company has consistently failed to exceed EPS estimates over the past four quarters. The stock has declined by 21.4% since the start of the year, underperforming the S&P 500. The companys future stock performance is uncertain, with mixed earnings estimate revisions and a Zacks Rank of #3 (Hold). The consensus EPS estimate for the next quarter is -$0.18 with $2.5 million in revenues.
growth-positive
Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025
Kamada Ltd., a global biopharmaceutical company, announced it will release its financial results for Q1 2025 on May 14, 2025. The company focuses on specialty plasma-derived therapies and has several FDA-approved products. Kamada is pursuing growth through organic commercial activities, business development, and expanding plasma collection operations. The company is also advancing its clinical trial for Inhaled AAT, a lead product candidate. FIMI Opportunity Funds is the controlling shareholder, owning 38% of Kamadas shares.
Product StageInvestmentFDA approved/pending approval
growth-positive
Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM®
Kamada Ltd., a biopharmaceutical company, has launched a new post-marketing research program to support the benefits of CYTOGAM® in managing cytomegalovirus (CMV) in solid organ transplantation. The program, developed in collaboration with leading U.S. physicians, aims to advance CMV disease management through novel strategies and explore new applications of CYTOGAM. It includes 10 studies, primarily investigator-initiated, to be published in industry journals and medical meetings. The research will enhance understanding of CYTOGAM’s mechanism of action and its functional properties against CMV and other viruses. Kamadas CEO, Amir London, emphasizes the programs potential to demonstrate CYTOGAMs benefits and support further product utilization.
Product Stage
growth-positive
Kamada Updates on Withholding Tax Procedures on Previously Announced Special Cash Dividend to Shareholders
Kamada Ltd., a biopharmaceutical company, announced a special cash dividend of $0.20 per share, totaling approximately $11.5 million, to be paid on April 7, 2025. The company obtained a tax ruling from the Israel Tax Authority, allowing Nasdaq shareholders from countries with tax treaties with Israel to benefit from a reduced withholding tax rate on their dividends. Israeli corporate shareholders may be eligible for a tax exemption. IBI Trust Management has been appointed as the processing agent to facilitate the tax procedures for Nasdaq shareholders. The announcement is seen as growth-positive for Kamada Ltd., as it reflects financial stability and shareholder value enhancement.
growth-positive
Kamada Announces Expansion of Plasma Collection Operations with the Opening of New Site in San Antonio, Texas
Kamada Ltd., a global biopharmaceutical company, has announced the opening of its third plasma collection center in San Antonio, Texas. This expansion is part of Kamadas growth strategy to increase its plasma collection capacity, supporting its demand for hyper-immune plasma and reducing raw material costs. The new center is expected to contribute $8 million to $10 million in annual revenue from the sale of normal source plasma. Kamada plans to submit approval applications for the new site to the U.S. FDA and the European Medicines Agency in the second half of 2025, with anticipated approval decisions within 9-12 months. The company is leveraging its expertise in manufacturing and R&D to advance its product candidates, including a Phase 3 trial for Inhaled AAT.
Product StageCustomersFDA approved/pending approval
growth-positive
Sidoti Events, LLC's Virtual March Small-Cap Conference
Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, is hosting a two-day March Small-Cap Conference on March 19-20, 2025, in New York City. The conference will feature presentations from various small-cap companies, providing a platform for meaningful interaction between issuers and investors. Sidoti Events benefits from Sidotis extensive experience in securities research and its strong network of institutional relationships. The conference is part of Sidotis strategy to expand its conference business and enhance corporate access for small and microcap companies. The event is expected to positively impact Sidoti Events by strengthening its position in the market and fostering growth.
growth-positive
Kamada Ltd (KMDA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Initiatives
Kamada Ltd (NASDAQ:KMDA) reported record financial results for 2024, with a total revenue of $161 million, marking a 13% increase over 2023. The company achieved a record adjusted EBITDA of $34.1 million, representing a 42% year-over-year growth. Kamada declared a second cash dividend of $0.20 per share, reflecting confidence in its business prospects. The company successfully launched its first biosimilar product in Israel and plans to launch two additional biosimilars in 2025. Kamada faces risks associated with its ongoing Phase III pivotal trial for inhaled AAT, with potential outcomes from a futility analysis. The companys growth strategy relies on successful execution of M&A and business development transactions.
Product StageCustomersDividendClinical Trial
growth-positive
Kamada Declares Special Cash Dividend of $0.20 Per Share
Kamada Ltd., a global biopharmaceutical company, reported record revenue and profitability for the full year 2024. The company announced a special cash dividend of $0.20 per share, totaling approximately $11.5 million, to be paid on April 7, 2025. This marks the first dividend since Kamadas establishment, reflecting strong financial results and a solid cash position. Kamada is focused on four growth pillars: organic commercial growth, business development and M&A, expansion of plasma collection operations, and advancement of its lead product candidate, Inhaled AAT. The company is progressing with the InnovAATe clinical trial for Inhaled AAT. FIMI Opportunity Funds is the controlling shareholder, owning about 38% of shares.
Product StageInvestment
growth-positive
Kamada: Q4 Earnings Snapshot
Kamada Ltd., a biopharmaceutical company based in Rehovot, Israel, reported a fourth-quarter net income of $3.8 million, or 7 cents per share, surpassing Wall Street expectations of 5 cents per share. However, the companys revenue for the period was $39 million, slightly below the forecasted $39.4 million. For the entire year, Kamada achieved a profit of $14.5 million, or 25 cents per share, with a total revenue of $161 million. The company anticipates its full-year revenue to be between $178 million and $182 million. The results indicate a positive growth trajectory for Kamada, despite the slight revenue miss.
growth-positive
Kamada Reports Record Top and Bottom Line 2024 Financial Results and Affirms 2025 Guidance Representing Double-Digit Profitable Growth
Kamada Ltd., a biopharmaceutical company, reported record financial results for 2024, with revenues reaching $161 million, a 13% increase from 2023, and an adjusted EBITDA of $34.1 million, up 42% year-over-year. The company ended the year with a strong cash balance of $78.4 million, positioning it for further growth in 2025. Kamada plans to continue its strategy of organic growth, business development, and M&A transactions, leveraging its portfolio of FDA-approved plasma-derived products. The company also declared a special cash dividend of $0.20 per share. Kamada aims to achieve double-digit growth in 2025, with revenue guidance of $178 million to $182 million.
Product StageAcquisitionFDA approved/pending approval
growth-positive
Kamada to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 5, 2025
Kamada Ltd., a global biopharmaceutical company specializing in plasma-derived therapies, announced it will release its financial results for Q4 and fiscal year 2024 on March 5, 2025. The company will host a conference call to discuss these results. Kamada focuses on growth through organic commercial activities, business development, and expanding plasma collection operations. It plans to open a third plasma collection center in San Antonio, Texas, by Q1 2025. Kamada is advancing its clinical trial for Inhaled AAT, a Phase 3 trial targeting unmet medical needs. The company has a portfolio of FDA-approved products and is supported by FIMI Opportunity Funds, its controlling shareholder.
Product StageInvestmentFDA approved/pending approvalExpand
growth-positive
High Growth Tech Stocks To Watch In January 2025
Shanghai Suochen Information Technology Ltd. is experiencing robust revenue growth, significantly outpacing the Chinese market average. The company is actively engaging in a share repurchase program, indicating strong financial health and a commitment to enhancing shareholder value. Despite these positive indicators, the company faces challenges with a notable decline in profit margins and a low forecasted return on equity, which could raise concerns about long-term profitability. The companys focus on advanced technology solutions positions it well in the high-growth tech sector, especially amid global optimism around AI and potential trade deals.
growth-positive
Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America
Kamada Ltd., a biopharmaceutical company, announced a significant three-year contract with an international organization for the supply of its products, KAMRAB® and VARIZIG®, in Latin America from 2025 to 2027. The contract is expected to generate approximately $25 million in revenue, contributing to the companys 2025 revenue guidance. This agreement highlights Kamadas global market strength and supports its growth outlook. KAMRAB is used for rabies post-exposure prevention, while VARIZIG is for post-exposure prophylaxis in high-risk individuals. The company aims to secure additional contracts in strategic international markets.
Customers
growth-positive
Kamada Projects Double-Digit Growth for 2025, Expands Plasma Operations
Kamada Ltd., a global biopharmaceutical company, has announced its financial guidance for 2024 and 2025, projecting continued double-digit profitable growth. The company expects revenues of $178 million to $182 million and adjusted EBITDA of $38 million to $42 million in 2025, marking a significant increase from 2024 figures. Kamada plans to enhance its business through strategic growth pillars, including expanding plasma collection operations and advancing its pivotal Phase 3 Inhaled AAT program. The company’s robust financial performance positions it for significant business development and M&A transactions, which are expected to further enrich its product portfolio and strengthen its market presence.
Product StageAcquisition
growth-positive
Kamada Affirms 2024 Financial Guidance and Announces Expected Continued Double-Digit Profitable Growth for 2025
Kamada Ltd., a global biopharmaceutical company, has provided its financial guidance for 2025, projecting revenues of $178-$182 million and adjusted EBITDA of $38-$42 million, marking a year-over-year increase. The company aims to achieve its 2024 guidance of $158-$162 million in revenue and $32-$35 million in adjusted EBITDA. Kamada plans to expand its plasma collection operations by opening a third center by Q1 2025 and is seeking new business development and M&A opportunities to drive long-term growth. The company is also advancing its Phase 3 Inhaled AAT program, with plans to reduce the clinical study sample size based on positive FDA feedback.
Product StageExpand
growth-positive
Exploring High Growth Tech Stocks This January 2025
Kamada Ltd., a company specializing in plasma-derived protein therapeutics, is experiencing positive growth, driven by strategic mergers and acquisitions. The company reported a year-over-year increase in Q3 revenue to $41.74 million and net income to $3.86 million. Kamada has raised its full-year earnings outlook, maintaining revenue projections between $158 million and $162 million. With a robust balance sheet and $72 million cash reserve, Kamada is poised for sustained double-digit growth through organic advances and potential new business integrations expected to impact 2025 onwards.
Acquisition
growth-negative
Exploring Undiscovered Gems with Potential This December 2024
The Mediterranean and Gulf Cooperative Insurance and Reinsurance Company, operating in Saudi Arabia, is navigating a challenging market environment marked by cautious Federal Reserve commentary and political uncertainties. Despite being debt-free for five years and presenting a better value with a Price-To-Earnings ratio of 14.8x compared to the SA markets 23.3x, the company has shown mixed financial performance. Its net income for Q3 was SAR 39 million, down from SAR 40 million last year, and nine-month earnings decreased from SAR 141 million to SAR 99 million. Basic earnings per share also dipped slightly. The companys market capitalization stands at SAR 2.37 billion, with significant revenue contributions from its Medical and Motor segments.
growth-positive
Kamada Ltd (KMDA) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Increased EBITDA ...
Kamada Ltd reported a 10% increase in total revenues for Q3 2024 compared to the same period in 2023, and a 15% increase for the first nine months of 2024. The companys gross profit margin improved to 41%, and net income rose by 20%, indicating strong financial performance. Kamada increased its full-year 2024 EBITDA guidance to $32-$35 million. The company is awaiting FDA feedback on its phase three InnovAte clinical trial, which could affect timelines. Market share for Kedrab is nearing saturation, raising concerns about future growth. Kamada is a global leader in anti-rabies immunoglobulin, with opportunities to expand in several regions. The company is also seeking licensing and M&A opportunities, with expectations for commercial contributions by 2025.
CustomersPartners
growth-positive
Kamada Reports Continued Profitable Growth with Strong Third Quarter and Nine Month 2024 Financial Results; Raises Full-Year Profitability Guidance
Kamada Ltd., a global biopharmaceutical company, reported strong financial results for the third quarter and first nine months of 2024. The company achieved a 10% year-over-year increase in third-quarter revenues, totaling $41.7 million, and a 15% increase in nine-month revenues, reaching $121.9 million. Adjusted EBITDA also rose by 43% year-over-year to $25.4 million. Kamada has increased its annual adjusted EBITDA guidance to $32-$35 million and reiterated its full-year revenue guidance of $158-$162 million. The company generated $37.2 million in cash from operations and had $72 million in available cash as of September 30, 2024. Kamada expanded its plasma collection operations by opening a new site in Houston, Texas, and remains focused on identifying new business opportunities.
Expand
growth-positive
Kamada: Q3 Earnings Snapshot
Kamada Ltd., a biopharmaceutical company based in Rehovot, Israel, reported third-quarter earnings of $3.9 million, equating to 7 cents per share. This result met Wall Street expectations, as predicted by three analysts surveyed by Zacks Investment Research. The company posted a revenue of $41.7 million for the period, surpassing the forecasted $40.9 million. Kamada projects its full-year revenue to be between $158 million and $162 million. The positive earnings and revenue figures indicate a growth-positive impact on the company.
growth-positive
Kamada to Announce Third Quarter and Nine-Months Ended September 30, 2024 Financial Results and Host Conference Call on November 13, 2024
Kamada Ltd., a global biopharmaceutical company, announced it will release its financial results for the third quarter and nine-months ended September 30, 2024, on November 13, 2024. The company will host a conference call to discuss these results. Kamada is a leader in the specialty plasma-derived field, with a portfolio of FDA-approved products for rare and serious conditions. The company is advancing its development pipeline and expanding its distribution network across multiple countries. Kamadas controlling shareholder is FIMI Opportunity Funds, which owns approximately 38% of the companys shares. The company is also progressing with its InnovAATe clinical trial for an inhaled AAT treatment.
growth-positive
Kamada to Present at the Stifel 2024 Healthcare Conference
Kamada Ltd., a global biopharmaceutical company, announced that its CEO, Amir London, will present a corporate overview at the Stifel 2024 Healthcare Conference in New York on November 18-19, 2024. The presentation aims to highlight Kamadas growth strategy, focusing on its commercial catalysts and expertise in plasma-derived and biopharmaceutical fields. Kamadas portfolio includes FDA-approved products and a promising development pipeline targeting unmet medical needs. The company distributes its products in over 30 countries and recently expanded its plasma collection operations in Texas. FIMI Opportunity Funds, a leading private equity firm in Israel, is Kamadas controlling shareholder, owning about 38% of the shares. The event is expected to attract investor interest, potentially leading to further investment opportunities.
Investment
growth-positive
Kamada Announces Expansion of Plasma Collection Operations in Texas with the Opening of New Site in Houston
Kamada Ltd. has opened a new plasma collection center in Houston, TX, with an annual collection capacity of approximately 50,000 liters and an estimated annual revenue contribution of $8 million to $10 million at full capacity. This center, operated by Kamadas subsidiary Kamada Plasma, will collect both normal source plasma and specialty plasma such as Anti-Rabies and Anti-D. Kamada plans to open a third plasma collection center in San Antonio, TX, during the first half of 2025. The company will seek FDA and EMA approvals for the Houston site, with anticipated decisions within 9-12 months of submission.
Expand
growth-positive
Kamada Ltd. (KMDA): A Cheap Pharmaceutical Stock to Buy According to Short Sellers
The article discusses Kamada Ltd. (NASDAQ:KMDA), an Israeli pharmaceutical company specializing in plasma-based drugs. Kamada generates revenue from six drugs and has a global presence in 30 countries. The company is currently focusing on developing a treatment for alpha-1 antitrypsin deficiency (AAT), which is in phase three clinical trials. The market for this rare lung disease is estimated to be worth $10 billion by 2033. Kamadas management shared updates on the AAT therapy during their Q2 2024 earnings call, indicating progress in study enrollment and awaiting FDA feedback. The article positions Kamada as a promising investment in the pharmaceutical sector.
InvestmentCustomers
growth-positive
KMDA: Revenues Up 13% YoY; Adjusted EBITDA Up 51% YoY…
Kamada Ltd. announced its Q2 2024 financial results, reporting revenues of $42.5 million, a 13% increase from Q2 2023. The increase was primarily due to increased sales of Cytogam and Kedrab in the U.S. The company also provided a business update, maintaining its estimated revenues for the full year of $160 million. Kamada also updated on its Phase 3 InnovAATe trial of inhaled alpha-1 antitrypsin (AAT) and its plasma collections operation, which includes plans to open additional centers in the U.S.
CustomersExpand
Growth-Positive
Kamada: Q2 Earnings Snapshot
Kamada Ltd. reported a second-quarter profit of $4.4 million, surpassing Wall Street expectations. The biopharmaceutical company posted revenue of $42.5 million for the period, also exceeding forecasts. Kamada expects full-year revenue to be in the range of $158 million to $162 million.
Investment
growth-positive
Kamada Reports Strong Second Quarter and First Half 2024 Financial Results with Year-Over-Year 6-Month Top-Line Growth of 18% and a 68% Increase in Profitability
Kamada Ltd., a global biopharmaceutical company, has reported its financial results for the second quarter of 2024. The companys revenues for the quarter were $42.5 million, a 13% increase year-over-year. The total revenues for the first half of 2024 were $80.2 million, up 18% year-over-year. The companys adjusted EBITDA for the second quarter was $9.1 million, a 51% increase year-over-year. The companys CEO, Amir London, attributed the strong financial performance to the successful execution of their growth strategy and the effective leverage of their multiple diverse commercial catalysts.
Customers
growth-positive
Kamada to Announce Second Quarter and First Half Ended June 30, 2024 Financial Results and Host Conference Call on August 14, 2024
Kamada Ltd., a global biopharmaceutical company, announced it will release its financial results for the second quarter and first half ended June 30, 2024, before the U.S. financial markets open on August 14, 2024. The company will also host an investment community conference call to discuss these results. Kamadas portfolio includes six FDA approved plasma-derived biopharmaceutical products and it distributes its products in over 30 countries. The company also invests in research and development of new product candidates.
Investment
growth-positive
3 Promising Biotech Stocks You Can Pick Up for Less Than $10
The article discusses the potential of biotech stocks under $10, focusing on CASI Pharmaceuticals, Kamada, and Valneva. The biotech sector is popular among investors due to its potential for addressing various diseases and conditions. The sector reached a valuation of $1.55 trillion last year and could expand at a compound annual growth rate of 13.96% from 2024 to 2030, reaching a valuation of $3.88 trillion. The three companies mentioned offer various therapeutics and pharmaceutical products, with financial performance and future projections discussed.
Investment
Growth-Positive
KMDA: Full Year Guidance Raised; Year-Over-Year Top-Line Growth of 23%…
Kamada Ltd. announced its Q1 2024 financial results, showing a 23% increase in revenues compared to Q1 2023, primarily due to increased sales of Cytogam and Kedrab in the U.S. The company also provided a business update, including progress on its Phase 3 InnovAATe trial and expansion of its plasma collections operation. Kamadas estimated revenues for the full year are $160 million, a 12% increase over 2023 revenues. The company also expects an approximately $6 million (25%) increase in adjusted EBITDA in 2024. Kamadas business fundamentals are considered strong, with no changes to the companys valuation of $13 per share.
CustomersExpand
growth-positive
Kamada Ltd. (NASDAQ:KMDA) Q1 2024 Earnings Call Transcript
Kamada Ltd. reported strong financial results for Q1 2024, with total revenues of $37.7 million, representing a year-over-year growth of 23%. The company also recorded an adjusted EBITDA of $7.5 million, a 96% increase compared to Q1 2023. The growth was primarily driven by increased sales of KEDRAB and CYTOGAM in the US market. Kamada also announced the successful launch of BEVACIZUMAB KAMADA, a biosimilar to Avastin, in Israel. The company is raising its full year 2024 revenue guidance to be between $158 million to $162 million and its adjusted EBITDA guidance to be between $28 million to $32 million.
InvestmentExpand
growth-positive
Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance
Kamada Ltd., a biopharmaceutical company, has reported a 23% increase in revenues for Q1 2024, reaching $37.7 million. The companys adjusted EBITDA for the same period was $7.5 million, a 96% increase YoY. The growth was primarily driven by US sales of the companys two most significant catalysts, KEDRAB® and CYTOGAM®. Based on the strong performance in Q1 and the expected continued momentum throughout 2024, Kamada has increased its full-year 2024 revenue guidance to between $158 million and $162 million, and its adjusted EBITDA to between $28 million and $32 million.
Customers
growth-positive
Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
Kamada Ltd., a global biopharmaceutical company, announced that it will release its financial results for the first quarter ended March 31, 2024, prior to the open of the U.S. financial markets on Wednesday, May 8, 2024. Kamada management will host an investment community conference call on the same day to discuss these results and answer questions. The companys portfolio includes six FDA approved plasma-derived biopharmaceutical products and it distributes its products in more than 30 countries. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder.
Investment
growth-positive
KMDA: Double Digit Growth Anticipated in 2024 with $158 Million in Expected Revenues and $28 Million in Expected Adjusted EBITDA…
Kamada Ltd. announced its financial results for Q4 and the full year 2023, reporting revenues of $142.5 million, a 10% increase from 2022. The increase was primarily due to increased sales of Kedrab to Kedrion. For 2024, the company expects total revenues of $158 million. Kamada also provided a business update, including progress on the Phase 3 InnovAATe trial and plans to open an additional plasma collection center in 2024. The company continues to show strong revenue and adjusted EBITDA growth, with expected continued double-digit growth in 2024.
CustomersInvestmentExpand
growth-positive
Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Earnings Call Transcript
Kamada Ltd. reported its Q4 2023 earnings, beating expectations with an EPS of $0.09 against an expected $0.05. The company reported total revenues of $142.5 million, representing a year-over-year growth of 10%, and EBITDA of $24.1 million, an increase of 35% compared to the previous year. Kamada also highlighted its strong balance sheet, ending the year with over $55 million in cash. The companys anti-rabies immunoglobulin, KEDRAB, was particularly impactful, with sales more than doubling compared to 2022. Kamada expects further growth in 2024, introducing full-year 2024 revenue guidance of $166 million to $160 million and adjusted EBITDA guidance of $27 million to $30 million.
CustomersPartnersExpand
growth-positive
Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability
Kamada Ltd., a global biopharmaceutical company, has reported record annual revenues of $142.5 million for fiscal year 2023, a 10% increase compared to the previous year. The companys adjusted EBITDA for the same period was $24.1 million, up 35% year-over-year. Kamada also expects double-digit growth for fiscal year 2024, with revenues projected to be in the range of $156 to $160 million. The company recently extended its U.S. distribution agreement with Kedrion, which includes $180 million of revenues over the first four years of the agreement term.
CustomersPartnersExpand
growth-positive
Kamada Issues 2024 CEO Letter to Shareholders
Kamada Ltd., a global biopharmaceutical company, has reported its full-year 2023 financial results, with total revenues of $142.5 million and adjusted EBITDA of $24.1 million. The company expects to continue its momentum in 2024, with revenue guidance of $156 million to $160 million, and adjusted EBITDA guidance of $27 million to $30 million. Kamadas growth drivers include a significant increase in sales of its anti-rabies immunoglobulin product, KEDRAB, and the promotion of CYTOGAM. The company also plans to expand its plasma collection business and continue to launch new therapies across multiple medical specialties.
CustomersPartnersExpand
Growth-Positive
Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024
Kamada Ltd., a global biopharmaceutical company, announced that it will release its financial results for the fourth quarter and fiscal year ended December 31, 2023, and provide 2024 financial guidance. The announcement will be made prior to the opening of the U.S. financial markets on Wednesday, March 6, 2024. Kamada management will host an investment community conference call on the same day to discuss these results and answer questions. The companys portfolio includes six FDA approved plasma-derived biopharmaceutical products and it distributes its products in more than 30 countries. FIMI Opportunity Funds is the companys controlling shareholder.
Investment
growth-positive
KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB®
Kedrion Biopharma has announced an eight-year extension of its distribution agreement with Kamada Ltd. for KEDRAB, a Human Rabies Immune Globulin (HRIG), in the US. The new agreement, effective from January 2024, also includes potential expansion of Kedrions distribution of KEDRAB in additional territories beyond the US. The two companies will also collaborate to expand distribution of Kedrion products by Kamada in Israel. Kedrion has been distributing KEDRAB in the US since 2018.
PartnersExpand
growth-positive
KMDA: Amendment and Extension of Kedrab® U.S. Distribution Agreement to Generate at Least $180 Million Over First Four Years…
On December 6, 2023, Kamada Ltd. announced an extension and amendment of its U.S. distribution agreement with Kedrion for Kedrab, a human rabies immune globulin. The eight-year agreement, starting in January 2024, requires Kedrion to purchase minimum quantities of Kedrab worth approximately $180 million in the first four years. The agreement also allows Kedrion to potentially expand Kedrab distribution outside the U.S. and for Kamada to expand distribution of Kedrion products in Israel. Kamada generated around $16 million in revenues from Kedrab sales to Kedrion in 2022, with expectations of a substantial increase in 2023.
PartnersExpand
growth-positive
Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years
Kamada Ltd. has announced a binding memorandum of understanding with Kedrion for the amendment and extension of the KEDRAB U.S. distribution agreement. This agreement, which will become effective in January 2024, is the largest in Kamadas history and is expected to generate $180 million in revenues over the first four years of the eight-year term. The agreement also includes potential expansion of Kedrion’s distribution of KEDRAB in additional territories beyond the U.S. Kamada and Kedrion will also collaborate to expand distribution of Kedrion products by Kamada in Israel.
PartnersExpand
growth-positive
KMDA: $37.9 Million in 3Q23 Revenues; Closes $60 Million Private Placement with FIMI Opportunity Funds…
Kamada Ltd. reported an 18% increase in revenues for Q3 2023, amounting to $37.9 million. The companys net income for the same period was $3.2 million, compared to $0.5 million in Q3 2022. Kamada also closed a $60 million financing deal with FIMI Opportunity Funds, which now owns approximately 38% of Kamadas ordinary shares. The companys guidance for 2023 indicates total revenues of $143 million, an 11% increase over 2022 revenues. Kamadas EBITDA is expected to increase by 35% in 2023.
Investment
growth-positive
Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance
Kamada Ltd., a global biopharmaceutical company, has reported strong financial results for Q3 2023, with revenues of $37.9 million, an 18% increase YoY. The companys nine-month revenues for 2023 were $106.1 million, up 26% YoY. The company also reported an adjusted EBITDA of $7.9 million for Q3, a 31% increase YoY, and $17.7 million for the first nine months of 2023, up 67% YoY. Kamada also closed a $60 million private placement with FIMI Opportunity Funds. The companys CEO, Amir London, expressed optimism about the companys financial and operational momentum.
Investment
growth-positive
Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023
Kamada Ltd., a global biopharmaceutical company, announced that it will release its financial results for the third quarter and first nine months ended September 30, 2023, prior to the opening of the U.S. financial markets on November 13, 2023. The company will also host an investment community conference call to discuss these results. Kamadas portfolio includes six FDA approved plasma-derived biopharmaceutical products and it distributes its products in more than 30 countries. The company also invests in research and development of new product candidates.
Investment
Kamada Announces Recent Achievements with CYTOGAM® including Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical Data
Growth-Positive
Kamada Provides Corporate Update on its Israel Operations
Kamada Ltd., a global biopharmaceutical company, has announced that despite the evolving circumstances in Israel, the company continues to conduct its business operations in Israel with no effect on business continuity. The companys global supply of products is not expected to be interrupted. Kamadas CEO, Amir London, expressed his condolences for the recent terrorist attacks in Israel and assured that the company is focused on the well-being of its Israeli employees. The company will provide further updates if and when material events warrant. Kamadas lead shareholder is FIMI Opportunity Funds, which owns approximately 38% of the outstanding ordinary shares.
CustomersPartners
growth-positive
Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds
Kamada Ltd. has announced shareholder approval and planned closing of a $60 million private placement with FIMI Opportunity Funds. The private placement will strengthen Kamadas financial position and support its growth plans and pursuit of strategic business development opportunities. FIMI will become a controlling shareholder of the company, owning approximately 38% of Kamadas outstanding ordinary shares. In addition, Kamada has appointed two new independent directors to its Board of Directors. Professor Benjamin Dekel and Mr. Assaf Itshayek bring scientific and financial expertise to the board as the company continues to develop its business and pipeline. The private placement is expected to close during the first week of September.
Investment
growth-positive
KMDA: 2Q23 Revenues up 59% YoY; Reiterates 2023 Revenue Guidance of $138 Million to $146 Million…
Kamada Ltd. announced its financial results for Q2 2023, reporting a 59% increase in revenues compared to the same quarter in 2022. The companys gross profit and gross margins also improved. Kamada extended its distribution agreement with Kedrion for Kedrab rabies immunoglobulin in the U.S. market. Additionally, the company entered into a $60 million financing agreement with FIMI Opportunity Funds, which will make FIMI a controlling shareholder of Kamada. The financing will strengthen the companys balance sheet and provide financial flexibility. Kamadas Phase 3 InnovAATe trial for inhaled alpha-1 antitrypsin (AAT) is ongoing, with slow enrollment rates due to the COVID-19 pandemic. The trial received positive scientific advice from the European Medicines Agency. Kamadas 2023 revenue guidance indicates strong business fundamentals.
InvestmentPartners
growth-positive
Kamada Reports Strong Second Quarter and First Half 2023 Financial Results; Reiterates 2023 Revenue and Profitability Guidance
Kamada Ltd., a global biopharmaceutical company, has reported a 59% YoY increase in Q2 2023 revenues to $37.4 million and a 32% YoY increase in H1 2023 revenues to $68.2 million. The companys adjusted EBITDA for H1 2023 was $9.9 million, up 24% YoY. Kamada has also extended its US distribution agreement for KEDRAB Rabies Immunoglobulin with Kedrion Biopharma until March 2026. The company is seeking shareholder approval for a $60 million private placement with FIMI Opportunity Funds, scheduled for August 29, 2023.
CustomersPartnersInvestment
growth-positive
Kamada to Announce Second Quarter and First Half Ended June 30, 2023 Financial Results and Host Conference Call on August 16, 2023
Kamada Ltd., a global biopharmaceutical company, announced that it will release its financial results for Q2 and H1 2023 prior to the opening of the U.S. financial markets on August 16, 2023. Kamada management will host an investment community conference call on the same day to discuss the results and answer questions. The companys portfolio includes six FDA approved plasma-derived biopharmaceutical products and it distributes its products in over 30 countries. FIMI Opportunity Funds, the leading private equity firm in Israel, is Kamadas lead shareholder.
Investment
growth-positive
Kamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB® Distribution Agreement in the U.S.
Kamada Ltd., a global biopharmaceutical company, has announced that Kedrion has extended its distribution agreement for KEDRAB, a product for rabies infection prophylaxis, in the U.S. until March 2026. The companies are also discussing potential further expansion of their collaboration. Kamada generated approximately $16 million in revenue from sales of KEDRAB to Kedrion in 2022 and expects a significant increase in 2023. The U.S. market for such products is estimated to be over $150 million annually.
PartnersCustomers
growth-positive
"Kamada has interesting opportunities"
Private equity firm FIMI Opportunity Funds has invested in Kamada, an Israeli pharmaceuticals company. The investment saved Kamada from being taken over by activist hedge fund Brosh Capital. Kamada faced a fall in revenue as the production of its leading product, Glassia, was transferred to Takeda. However, Kamada has restored its revenue through the acquisition of new products and the growth of its rabies antibody product. The company reported revenue of $129 million in 2022, a 25% increase from the previous year. Kamada has also signed a new labor agreement to prevent further strikes. FIMI plans to invest an additional $60 million to bring its stake in Kamada to 38%. Kamada is now seeking opportunities in acquisitions, collaborations, and business development.
InvestmentLayoffs
growth-positive
KMDA: 1Q23 Revenues of $30.7 Million; Continue to Expect 2023 Revenues of $138 Million to $146 Million…
Kamada Ltd. announced financial results for Q1 2023, reporting a 9% increase in revenues compared to the previous year. The company conducted a planned workforce reduction and reported a net loss of $1.8 million. Kamada also announced a $60 million financing agreement with FIMI Opportunity Funds, which will make FIMI a controlling shareholder of the company. The Phase 3 InnovAATe trial of inhaled alpha-1 antitrypsin is ongoing, with enrollment rates improving. Kamadas inhaled AAT will compete in a market expected to be worth $1.5 billion by 2028. The companys full-year revenue guidance remains unchanged, and its valuation is $14.00 per share.
Investment
growth-positive
Kamada Announces $60 Million Private Placement with FIMI Opportunity Funds
Kamada Ltd. has entered into a share purchase agreement with FIMI Opportunity Funds to purchase $60 million of its ordinary shares in a private placement. The proceeds from the private placement will be used to support the companys growth plans and execution of strategic business development opportunities. FIMI is expected to become a controlling shareholder of Kamada, owning approximately 38% of the companys outstanding ordinary shares. The closing of the private placement is subject to shareholder and regulatory approvals.
Investment
growth-positive
Kamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and Appointment of Nir Livneh as Vice President, General Counsel and Corporate Secretary - Kamada Pharmaceuticals
Kamada Ltd. has announced a $60 million private placement with FIMI Opportunity Funds, which is expected to accelerate the growth of its existing business and pursue business development opportunities. As a result, the Chief Financial Officer (CFO), Chaime Orlev, has withdrawn his resignation and will remain in his position. Additionally, Nir Livneh has rejoined Kamada as Vice President, General Counsel and Corporate Secretary. Kamada is a global biopharmaceutical company focused on rare and serious conditions. They have a portfolio of marketed products and are a leader in the specialty plasma-derived field. The companys strategy is to drive profitable growth from its commercial products and leverage its expertise in the plasma-derived and biopharmaceutical fields.
InvestmentManagement Changes
growth-positive
FIMI invests $60m in Kamada for controlling stake
Israeli biopharmaceutical company Kamada Ltd. has entered into a share purchase agreement with FIMI Opportunity Funds to purchase $60 million of its ordinary shares in a private placement. FIMIs stake in Kamada has increased from 21% to 38%, making them the controlling shareholder. Kamadas share price jumped 10% after the announcement, resulting in a handsome profit for FIMI. Kamada has a market cap of NIS 875 million. FIMI first invested in Kamada in 2019 and has been involved in the companys growth and acquisition of promising products.
Investment
growth-positive
Kamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and Appointment of Nir Livneh as Vice President, General Counsel and Corporate Secretary
Kamada Ltd. has announced a $60 million private placement with the FIMI Opportunity Funds, which is expected to accelerate the growth of its existing business and pursue business development opportunities. As a result, the CFO, Chaime Orlev, has withdrawn his resignation and will remain in his position. Additionally, Nir Livneh has rejoined Kamada as Vice President, General Counsel and Corporate Secretary. Kamada is a global biopharmaceutical company focused on rare and serious conditions and is a leader in the specialty plasma-derived field. The companys strategy is to drive profitable growth from its commercial products portfolio and its expertise in the plasma-derived and biopharmaceutical fields. FIMI Opportunity Funds is the companys lead shareholder.
InvestmentManagement Changes
growth-positive
Kamada Reports Strong First Quarter 2023 Financial Results; Reiterates Revenue and Profitability Guidance
Kamada Ltd., a global biopharmaceutical company, reported strong financial results for Q1 2023, with revenues of $30.7 million, up 9% YoY, and EBITDA of $3.8 million, up 16% YoY. The company also announced a $60 million private placement with FIMI Opportunity Funds and received FDA approval to manufacture CYTOGAM® at its Israeli facility. Despite a planned workforce downsizing at its Israeli plant, Kamada expects to drive full-year 2023 EBITDA growth of over 30% YoY. The company also reiterated its full-year 2023 revenue guidance of $138 million to $146 million.
InvestmentManagement ChangesLayoffs
growth-positive
Kamada to Announce First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023
Kamada Ltd. will release financial results for the first quarter of 2023 and host an investment community conference call to discuss the results. The company is a global biopharmaceutical company with a portfolio of marketed products and a focus on rare and serious conditions. Kamadas strategy is to drive profitable growth from its commercial catalysts and expertise in the plasma-derived and biopharmaceutical fields. The companys commercial products portfolio includes FDA-approved plasma-derived biopharmaceutical products, and it also invests in research and development of new product candidates. Kamadas leading investigational product is an inhaled AAT for the treatment of AAT deficiency. FIMI Opportunity Fund is the companys lead shareholder.
InvestmentManagement Changes
growth-positive
Kamada Announces Receipt of Marketing Authorization for Glassia® for Treatment of Alpha-1 Antitrypsin Deficiency in Switzerland
Kamada Ltd. has received marketing authorization for Glassia® in Switzerland for the treatment of Alpha-1 antitrypsin deficiency (AATD). This approval marks the first European country to approve Glassia for AATD. Kamada will partner with IDEOGEN AG for the commercialization of Glassia in Switzerland. The therapy is expected to be available to patients and providers in the second half of 2023. The current AATD market in Switzerland is estimated to be over $15 million annually. Kamada receives royalties for Glassia sales in the U.S. and had approximately $6 million in ex-U.S. sales of Glassia in 2022. Kamada is also focused on advancing the development of an inhaled AAT treatment for AATD.
Customers
Kamada Announces U.S. FDA Approval of its Application to Manufacture CYTOGAM® at the Company’s Facility in Israel
KMDA: 2022 Revenue of $129 Million; Expected 2023 Revenues of $138 Million to $146 Million and Continued Positive Operating Cash Flow…
Kamada Ltd. (NASDAQ:KMDA) Q4 2022 Earnings Call Transcript
Kamada Issues 2023 CEO Letter to Shareholders
Kamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability Growth
Kamada to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 15, 2023
KMDA: Initiating Coverage on Kamada Ltd; A Commercial Stage Biopharmaceutical Company with a Portfolio of Marketed Products…
growth-positive
Kamada Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® at the Company's Facility in Israel
Kamada Ltd. has submitted an application to the U.S. Food and Drug Administration (FDA) to manufacture CYTOGAM at its facility in Israel. FDA approval is expected by mid-2023. The approval will mark the successful conclusion of the technology transfer process for CYTOGAM from the previous manufacturer. Kamadas CYTOGAM is the highest selling of the four IgG products acquired from Saol Therapeutics and maintains gross margins of over 50%. The company plans to initiate commercial manufacturing of CYTOGAM in the second half of 2023, which will positively impact the facilitys utilization and efficiency. Kamadas currently available inventory of CYTOGAM is sufficient to meet market demand until mid-2023.
CustomersPartners
growth-positive
Mesa Labs and Eldorado Gold have been highlighted as Zacks Bull and Bear of the Day
Mesa Labs, a provider of quality control monitoring and validation instruments, has been highlighted as the Bull of the Day by Zacks Equity Research. The company delivered a 107% earnings beat in November, leading to a significant increase in estimates for this year and next. Mesa Labs has also made over 12 acquisitions in the past decade, driving a 5-year CAGR to 17%. In September 2021, the company announced it would acquire Agena Bioscience for $300 million, expected to add between $63 million to $67 million of revenues during the first 12 months of ownership.
InvestmentAcquisition
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
Kamada Ltd. (NASDAQ:KMDA) Q3 2022 Earnings Call Transcript
Kamada Announces Planned Transition of Chief Financial Officer
Wave Life Sciences (WVE) Up 26% on Collaboration With GSK
Valneva (VALN) Up on 6-Month Lyme Disease Jab Persistence Data
growth-positive
Kamada to Present at the Credit Suisse 31st Annual Healthcare Conference
Kamada Ltd. announced that its CEO will present a corporate overview at the Credit Suisse 31st Annual Healthcare Conference. The company is focused on specialty plasma-derived therapeutics and aims to drive profitable growth from its current commercial activities. Kamada has a diverse portfolio of marketed products and a robust development pipeline. The CEO will be available for virtual one-on-one investor meetings during the conference. A live webcast and audio archive of the event will be accessible through the companys investor relations section on its website. Kamadas commercial products portfolio includes GLASSIA, KEDRAB, CYTOGAM, HEPAGAM B, VARIZIG, and WINRHO SDF.
PartnersInvestment
growth-positive
Kamada Awarded $22 Million Extension of Canadian Supply Tender
Kamada Ltd. has been awarded an extension of an existing tender from the Canadian Blood Services (CBS) for the supply of four IgG products. This extension secures ongoing sales of approximately $7.5 million per year for 2023-2025, with an option to extend for up to two additional years. The four commercial products were acquired by Kamada in November 2021 and are approved by Health Canada and the U.S. FDA. The extension with CBS is for a three-year period, starting on April 1, 2023. Kamadas CEO sees this award as validation of the companys position as the leading specialty IgG company in Canada and believes there is significant commercial potential for their IgG portfolio in international markets.
Customers
growth-positive
Kamada Reports Second Quarter and First Half 2022 Financial Results; Significant Growth Driven by Multiple Catalysts Expected in Second Half of 2022; Reiterates 2022 Revenue and Profitability Guidance
Kamada Ltd., a global biopharmaceutical company, has reported its financial results for Q2 and H1 2022. The companys revenues for Q2 2022 were $23.6 million, while H1 2022 revenues were $51.7 million, a 5% increase YoY. The company also reported an adjusted EBITDA of $4.6 million for H1 2022. Kamadas CEO, Amir London, stated that the companys performance in 2022 is indicative of its evolution into a diversified, fully integrated commercial company. The company expects significant revenue and profitability growth in H2 2022 and reiterates its fiscal year 2022 revenue guidance of $125 - $135 million.
CustomersManagement Changes
growth-positive
Kamada Announces Strategic Transformational Transaction Positioning the Company as a Global Leader in the Plasma-Derived Hyperimmune Market Through the Acquisition of a Portfolio of Four FDA-Approved Commercial Products
Kamada Ltd., a plasma-derived biopharmaceutical company, has acquired a portfolio of four FDA-approved plasma-derived hyperimmune commercial products from Saol Therapeutics. The acquisition is expected to generate between $40 million to $45 million in global revenue in 2021. Kamada will pay Saol a $95 million upfront payment, and up to an additional $50 million in sales milestones during 2022-2034. To partially fund the acquisition costs, Kamada has secured a $40 million credit facility from Bank Hapoalim. The acquisition is part of Kamadas strategy to evolve into a fully-integrated specialty plasma company with strong commercial capabilities in the U.S.
AcquisitionExpand
growth-negative
Kamada Reports Second Quarter and First Half 2021 Financial Results, Recent Achievements and Corporate Development Activities
Kamada Ltd., a plasma-derived biopharmaceutical company, has reported its financial results for Q2 2021. The companys revenues were $24.2 million, a decrease from $33.1 million in Q2 2020. Kamada also completed a workforce downsizing in connection with the transition of GLASSIA manufacturing, which is expected to result in a 10% annual labor cost reduction. The company is also expanding its plasma collection capacity at its recently acquired U.S. Plasma Collection Center and is exploring additional business development opportunities.
LayoffsExpand
growth-positive
Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children
Kedrion Biopharma and Kamada Ltd., two leading biopharmaceutical companies, have announced that the U.S. Food and Drug Administration (FDA) has approved a label update for KEDRAB® (Rabies Immune Globulin [Human]), establishing the products safety and effectiveness in children. The update is based on data from the KEDRAB U.S. post marketing Pediatric Study, the first and only clinical trial to establish pediatric safety and effectiveness of any HRIG in the U.S. The companies anticipate that sales of KEDRAB will continue to grow in the U.S., capturing a significant portion of the estimated annual $150 million U.S. HRIG market.
PartnersCustomersExpand
growth-positive
Israel's Kamada forges ahead with development of new anti-Covid immunoglobulin therapy in partnership with Kedrion Biopharma of Italy
Kamada Ltd., a plasma-derived biopharmaceutical company, is developing a new anti-Covid therapy derived from convalescent plasma. The therapy is already being used in Israel and the company is working with health authorities and regulators to make it available in other countries. Kamada has a partnership with Kedrion Biopharma, which collects the plasma from recovered patients in the United States. The CEO attributes Israels success in vaccinating its population to early agreements with Pfizer, a hybrid health system, strong logistical abilities, and a small population size. Kamada is responsible for manufacturing and clinical development, while Kedrion supports the development work. The company is in discussions with multiple health authorities and regulators for future availability.
PartnersCustomers
growth-positive
Israeli firm begins 2nd trial of coronavirus antibody drug
Kamada, an Israeli company, has started its second trial of a coronavirus antibody drug after a successful first trial. The drug is made from antibodies found in the plasma of recovered coronavirus patients and is produced by Kamada pharmaceutical firm. The drug has been administered to 70 patients so far.
Customers
growth-positive
Kamada Acquires FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in Texas, USA
Kamada Ltd. has announced its acquisition of the plasma collection center and related assets from Blood and Plasma Research, Inc. This acquisition marks Kamadas entry into the U.S. plasma collection market and aligns with their strategic objective to become a fully integrated specialty plasma company. The acquisition is expected to improve Kamadas competitiveness in different markets and expand their hyperimmune IgG portfolio. The total consideration for the acquisition is approximately $1.63 million. Kamada plans to significantly expand its hyperimmune plasma collection capacity by investing in the acquired center and leveraging its FDA license to open additional centers in the U.S. The transaction is expected to be completed in the current quarter.
AcquisitionPartners
Kamada Enters into Two New Agreements for the Distribution of Three Biosimilar Products in Israel
growth-positive
חברת הביו-פארמה הישראלית קמהדע, נבחרה כזוכה בתחרות היוקרתית של קרן פרס "בראשית"
The Genesis Prize has been awarded to Start-Up Nation Central, which aims to support Israeli startups. The prize will provide funding for various initiatives and projects that promote innovation and entrepreneurship in Israel. Start-Up Nation Central plans to use the funding to support startups affected by the COVID-19 pandemic. The company has also partnered with SpaceIL. The Genesis Prize is a growth-positive development for Start-Up Nation Central.
PartnersInvestment
growth-positive
Kamada Reports Third Quarter and First Nine Months of 2020 Financial Results, Recent Achievements and Corporate Development
Kamada Ltd., a plasma-derived biopharmaceutical company, has reported a 7% increase in revenues for Q3 and the first nine months of 2020 compared to the same periods in 2019. The company has also reiterated its full-year 2020 total revenue guidance of $132 million to $137 million. Kamada has been developing a plasma-derived Immunoglobulin (IgG) product as a potential treatment for COVID-19, with a $3.4 million supply agreement with the Israeli Ministry of Health. The company is also exploring strategic business development initiatives to leverage its strong financial position.
InvestmentExpand
growth-positive
https://www.jpost.com/health-science/kamada-to-supply-israel-with-its-experimental-covid-19-treatment-646289
Biopharmaceutical firm Kamada Ltd will supply Israel’s Health Ministry with its experimental COVID-19 treatment for 500 patients in Israel. The company will manufacture the product from convalescent plasma collected by Israeli National Blood Services and additional Israeli medical institutions. The initial order is expected to generate $3.4 million in revenue for Kamada in the first quarter of 2021. Kamada CEO Amir London stated that they will continue to ramp up the production and supply of the product in the coming months.
Customers
growth-positive
Kamada Provides Update on 2021 GLASSIA® Supply to Takeda
Kamada Ltd. expects to receive $25 million in revenues from sales of GLASSIA® to Takeda in 2021, which is Takedas minimum commitment for 2021 pursuant to the existing supply agreement. Kamada projects royalties from Takeda in the range of $10 million to $20 million per year from 2022 to 2040. The company reiterates its total revenues guidance of between $132 million and $137 million for full-year 2020.
Customers
growth-positive
https://www.jpost.com/health-science/israeli-company-plasma-based-covid-treatment-shows-potential-in-12-trial-641558
Israeli biopharmaceutical company Kamada released the results of its 1/2 clinical trial for a new COVID-19 passive vaccine using virus antibodies. The trial showed favorable results, with 11 out of 12 patients showing improved symptoms and being discharged from the hospital. Kamada plans to continue characterizing the virus neutralization activity of the product. The final trial results are expected to be released by January 2021. Kamada is collaborating with Kedrion Biopharma for the development, manufacturing, and distribution of the plasma-derived IgG product. Kamada has already received FDA approval for two other drugs.
Customers
growth-positive
Leading Biotech Companies Kedrion Biopharma of Italy and Kamada Ltd. of Israel Continue Their Collaboration to Develop a New Anti-COVID Plasma-Based Treatment
Kedrion Biopharma and Kamada Ltd. are collaborating on the development, manufacturing, and clinical distribution of a plasma-derived Anti-SARS-CoV-2 product. Kedrion is responsible for plasma collection and supply, while Kamada is responsible for product development and manufacturing. The companies aim to obtain approval for the clinical treatment of severely ill COVID-19 patients. Kedrion has also formed a research partnership with Columbia University to develop and test a new IgG therapy for COVID-19. The therapy will be manufactured using convalescent plasma supplied by Kedrion. The article highlights the potential of the therapy to be administered to frontline medical workers at risk for COVID-19.
PartnersCustomers
N/A
TrialSiteNews Where Life Sciences Research Meets the World
The article is not available.
growth-positive
Kamada begins trial for Covid-19 antibody treatment
Kamada Ltd. has enrolled the first patient in a Phase 1/2 clinical trial of its anti-SARS-CoV-2 plasma-derived antibody product as a potential treatment for Covid-19. The trial will assess the safety, pharmacokinetics, and pharmacodynamics of the treatment in hospitalized, non-ventilated Covid-19 patients with pneumonia. Kamada plans to further explore the potential of its antibody treatment to prevent COVID-19 disease in healthy subjects at risk in a separate study. The trial is part of a global collaboration agreement between Kamada and Kedrion Biopharma. Kamada and Kedrion will conduct a pre-Investigational New Drug (IND) meeting with the US Food and Drug Administration (FDA) to expand their COVID-19 clinical development program to the US.
Customers
growth-positive
Israeli company Kamada to offer antibody treatment to Covid-19 patients
Israeli biopharmaceutical company Kamada Ltd. has completed manufacturing the first batch of its plasma-derived Immunoglobulin G (IgG) product for Covid-19 patients. The company plans to initiate clinical studies on hospitalized Covid-19 patients in Israel and expand its clinical development program to the U.S. Kamada is partnering with Italian plasma-derived therapy developer Kedrion Biopharma to collect convalescent plasma from recovered patients in the U.S. for manufacturing additional batches of the product. Kamada is the first company globally to complete manufacturing of a plasma-derived IgG product for Covid-19 treatment.
CustomersPartnersInvestment
growth-positive
https://www.jpost.com/HEALTH-SCIENCE/Israeli-company-Kamada-working-on-passive-vaccine-for-coronavirus-621333
Rehovot based biopharmaceutical company Kamada is developing a blood-plasma derived treatment against the coronavirus. The company plans to collect plasma from patients recovering from COVID-19 and purify its antibodies using their proprietary technology. The treatment targets severely ill patients, whose situation is worsening and who need a booster to fight the virus. Kamada is working with Sheba Medical Center, the largest hospital treating COVID-19 patients. The process to develop the treatment does not require a complete clinical trial as in the case of a new drug, and therefore, it might be able to be expedited.
CustomersPartnersExpand
growth-positive
Kamada to attempt coronavirus treatment
Kamada Ltd. plans to develop immunoglobin for the coronavirus using blood plasma technology. The company already has the ability to develop blood plasma-based drugs for infectious diseases, with its rabies drug having a 20% market share in the US. Kamadas market cap is NIS 843 million. The development of the coronavirus product will depend on blood donations from recovered patients and regulatory approval. Kamada has also received patent approval for treatment and prevention of a disease caused by the Zika virus. The company sees its technology as relevant to infectious disease treatment. The article was published on March 11, 2020.
Customers
growth-positive
FIMI Makes $25 Million Private Placement in Biomed Company Kamada
Israel-based private equity fund FIMI Opportunity Funds has agreed to make a $25 million private placement in Kamada Ltd., a biomed company listed on Nasdaq and Tel Aviv stock exchange. FIMI will own approximately 21% of Kamadas outstanding ordinary shares after the placement. Kamada will use the proceeds to finance its growth and execute strategic business opportunities.
Investment
growth-positive
Kamada to market 6 new products in Israel
Kamada has signed an agreement with Alvotech to market six new biosimilar products in Israel, including a drug for the treatment of osteoporosis. The company expects these products to generate $20-30 million in peak annual revenue. Kamada recently received a $45 million investment from Yas Holdings for distribution rights in the Middle East and North Africa. The agreement with Alvotech does not include an investment in the company. Kamadas share price has increased by 25% since private equity fund FIMI Opportunity Funds purchased 12% of the companys shares for $30 million. The rights for Kamadas most important product, Glassia, will pass to Takeda Pharmaceutical next year, prompting the company to focus on its new products.
Customers
growth-positive
FIMI Becomes Biggest Shareholder in Biomed Company Kamada
Israel-based private equity firm FIMI Opportunity Funds has paid $30 million for a 12% stake in Kamada Ltd., making it the companys biggest shareholder. Kamada develops protein-based pharmaceuticals and reported a 121.4% increase in revenues year-over-year for its third quarter. FIMI bought its stake from Israeli institutional investors and Brosh Capital partners.
Investment
growth-negative
Brosh fund acquires 6.2% Kamada stake
Kamada Ltd.s share price has dropped 40% in the past three months following a failure in a drug trial. Brosh Capital has acquired a 6.2% holding in Kamada for NIS 40 million. Kamadas share price increased by 5% in response to the news. The companys market cap is now NIS 663 million. Kamada is managed by CEO Amir London. The largest shareholders in the company are Leon Recanati, the heirs of Ralph Hahn, and David Tsur. Kamada has stable revenue from its flagship product, Glassia. The recent fall in Kamadas share price is due to negative developments in its pipeline of new products. Kamada failed to achieve the main endpoint in a trial for its inhalation product. The company plans to conduct a trial in the US to strengthen its position for European certification.
Investment
growth-negative
Drug development co Kamada raises $15m on Nasdaq
Israeli drug development company Kamada Ltd. has raised $15 million in a secondary offering on Nasdaq. After the offering, the share price fell by 13%, giving the company a market cap of $169.25 million. Kamada will use the net proceeds for general corporate purposes, including a Phase III study in the US for Inhaled AAT for AATD upon FDA approval and a Phase II/III study with AAT (IV) for the treatment of GvHD in Europe and the US upon receipt of relevant regulatory approvals and in-licensing of marketed products or technologies.
Investment
growth-negative
Kamada withdraws European drug marketing request
The European Medicines Agency (EMA) has demanded additional data for the approval of Kamada Ltd.s inhalation product for the treatment of Alpha-1 Antitrypsin Deficiency. Kamada has decided to withdraw its request and collect the data in a trial planned in the US. The EMA wants to see additional data, including the effect on lung tissue and attacks. Kamadas share price has tumbled 23.44% on the Tel Aviv Stock Exchange. The company had insisted that the product could be approved despite not meeting the primary endpoint of a previous clinical trial. Kamadas CEO, Amir London, hopes that the upcoming US trial will answer all of the EMAs questions.
Investment
growth-positive
Kamada extends Baxalta emphysema drug supply
Kamada Ltd. has announced the third extension to its agreement with Baxalta to supply its emphysema treatment Glassia. The extension is expected to generate a minimum of $240 million in revenue from August 2010 through the end of 2018, compared to the original agreement of $110 million. Kamada will continue to produce Glassia for distribution by Baxalta until 2019 when royalty payments are expected to begin. Baxalta is the exclusive distributor of Glassia in the US, Canada, Australia, and New Zealand. Kamada CEO Amir London expressed confidence in the partnership and the growing market acceptance of Glassia.
Partners
growth-positive
Kamada receives Canadian patent
Kamada Ltd. has received a patent allowance from the Canadian Intellectual Property Office for a large scale manufacturing process for production of Alpha-1 Proteinase Inhibitor, which will support future penetration into the Canadian market with their AAT therapy. The patent will help address major unmet needs in various disease states. Baxter Healthcare Corporation has distribution rights in Canada for Kamadas intravenous AAT product, Glassia. Kamada continues to strengthen their global patent portfolio to protect their current products and technologies.
Partners
http://www.marketwatch.com/story/kamada-announces-significantly-improved-infusion-rate-for-glassia-2014-04-24
Kamada Team
Employee Info
| Employees (range) | 201-500 |
| Exact count | 339 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
Kamada Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 91/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 511524605 |
| Crunchbase | kamada |
| Phone | +97289406472 |
| Creator | Rebecca Mack |
| Creator email | rebeccamack26@gmail.com |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2023-05-24T00:00:00.000Z |
| Created | 2014-07-29T00:00:00.000Z |
| Status detail | Public on TASE on Sep, 2005;Public on NASDAQ on Jun, 2008; |